Cargando…
Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach
Forty percent of patients with diffuse large B-cell lymphoma (DLBCL) show resistant disease to standard chemotherapy (CHOP) in combination with the anti-CD20 monoclonal antibody rituximab (R). Although many new anti-cancer drugs were developed in the last years, it is unclear which of these drugs ca...
Autores principales: | de Jong, Mathilde R. W., Visser, Lydia, Huls, Gerwin, Diepstra, Arjan, van Vugt, Marcel, Ammatuna, Emanuele, van Rijn, Rozemarijn S., Vellenga, Edo, van den Berg, Anke, Fehrmann, Rudolf S. N., van Meerten, Tom |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5831110/ https://www.ncbi.nlm.nih.gov/pubmed/29489886 http://dx.doi.org/10.1371/journal.pone.0193098 |
Ejemplares similares
-
WEE1 Inhibition Enhances Anti-Apoptotic Dependency as a Result of Premature Mitotic Entry and DNA Damage
por: de Jong, Mathilde Rikje Willemijn, et al.
Publicado: (2019) -
Tumour necrosis as assessed with (18)F-FDG PET is a potential prognostic marker in diffuse large B cell lymphoma independent of MYC rearrangements
por: Kahle, Xaver U., et al.
Publicado: (2019) -
Identification of the estrogen receptor beta as a possible new tamoxifen-sensitive target in diffuse large B-cell lymphoma
por: Langendonk, Myra, et al.
Publicado: (2022) -
Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis
por: He, Yuan, et al.
Publicado: (2019) -
Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: Diagnosis and Treatment
por: van Doesum, Jaap A., et al.
Publicado: (2021)